Urinary excretion of glycosaminoglycans in disseminated neoplasm

GERALD MANLEY, LYNNE BOWER, AND ANNA ANSON
From the Departments of Chemical Pathology and Medical Oncology, Torbay Hospital, Torquay, Devon, UK

SUMMARY Urinary glycosaminoglycan excretion was studied in 24 cases of disseminated neoplasm, 12 of which had unequivocal evidence of skeletal involvement. Urinary hydroxyproline, cetylpyridinium chloride (CPC)-precipitable uronic acid, and CPC-precipitable hexosamine were expressed as a ratio to urinary creatinine. Glycosaminoglycans contained in urine concentrated × 1000 by vacuum-dialysis were separated by electrophoresis on cellulose acetate and stained with alcian blue. Of the 12 cases with clear evidence of skeletal involvement, eight (66%) showed elevation of serum alkaline phosphatase, five (42%) showed elevation of urinary hydroxyproline, and three (25%) showed elevation of urinary uronic acid. It is concluded that urinary uronic acid is not a sensitive index of skeletal involvement in disseminated neoplasm.

The most striking feature of the study was the identification of a well-defined fraction indistinguishable from hyaluronic acid in seven (58%) of the cases with evidence of skeletal involvement. Hyaluronic acid is not normally identifiable in adult human urine. The hyaluronic acid excretors showed more consistent biochemical evidence of bone disease (elevation of serum alkaline phosphatase and urinary hydroxyproline) than the non-excretors. The possibility that the urinary hyaluronic acid is derived from degradation of skeletal hyaluronic acid is discussed. An alternative explanation is that the hyaluronic acid is derived from neoplastic cells as part of a reversion of glycosaminoglycan synthesis to a more 'fetal' state, a glycosaminoglycan counterpart of the production of oncofetal antigens by neoplastic cells.

Increased urinary excretion of hydroxyproline has been reported in cases of disseminated neoplasm with secondary deposits in bone (Platt et al., 1964). It is assumed that the increase in hydroxyproline excretion is the result of increased degradation of bone collagen, and it has been proposed that urinary hydroxyproline excretion provides a better index of bone erosion than serum alkaline phosphatase (Bonadonna et al., 1966; Hosley et al., 1966). Since glycosaminoglycans are associated with collagen in bone (Herring and Kent, 1961) it was decided to study the urinary glycosaminoglycan excretion in a group of patients with disseminated neoplasm to determine whether the excretion of these molecules is also increased in the presence of neoplastic invasion of bone.

Material and methods

Twenty-four patients with disseminated neoplasm attending the Department of Medical Oncology at Torbay Hospital were studied. Tissue diagnosis was obtained by needle-biopsy or from tissue removed at operation. Evidence of skeletal involvement was obtained by clinical examination and skeletal radiographs, serum alkaline phosphatase assay, and 24-hour urinary hydroxyproline excretion. Twenty-four-hour urinary glycosaminoglycan excretion was studied by uronic acid and hexosamine assays of glycosaminoglycans isolated by cetylpyridinium chloride (CPC) precipitation, and electrophoretic separation of urinary glycosaminoglycans concentrated by vacuum-dialysis. Control data for glycosaminoglycan excretion were drawn from 100 normal subjects of all ages studied by identical methods previously reported (Manley et al., 1968).
SERUM ALKALINE PHOSPHATASE
The method of Morgenstern et al. (1965) was employed, using a Technicon SMA-plus analyser.

URINE CREATININE
A single-channel Technicon Auto-Analyzer was used (AAI) employing Technicon method N-116 (alkaline picrate).

HYDROXYPROLINE ASSAY
Aliquots of 24-hour urine collections were assayed by the Hypronosticon Kit (Organon (Teknika) Limited, Cromwell Road, St. Neots, Huntingdon) based on the method of Goverde and Veenkamp (1972).

ISOLATION OF GLYCOSAMINOGLYCANS
Glycosaminoglycans were isolated from aliquots of 24-hour urine samples by CPC precipitation, followed by dissolution of the complex in sodium chloride and final precipitation in ethanol, according to the method of Manley et al. (1968).

URONIC ACID ASSAY
Glycosaminoglycans isolated from aliquots of urine (5 ml) were dissolved in water (1 ml), and the uronic acid content was determined by the method of Bitter and Muir (1962).

HEXOSAMINE ASSAY
Glycosaminoglycans isolated from aliquots of urine (5 ml) were hydrolysed with HCl (4 m) in sealed glass ampoules in an autoclave at 15 psi for 30 min, as described by Sobocinski et al. (1976). Hydrolysates were dried over KOH in vacuo, and hexosamine was assayed by Boas' (1953) modification of the Elson-Morgan reaction, as described by Manley and Williams (1969).

SEPARATION OF GLYCOSAMINOGLYCANS
Aliquots (50 ml) of 24-hour urine samples were concentrated × 1000 by vacuum-dialysis. Electrophoresis of urine concentrates (10 μl, equivalent to 10 ml original urine) was carried out on cellulose acetate membrane in veronal-acetate buffer, pH 9.2. Marker samples of hyaluronic acid (human umbilical cord), heparan sulphate (human aorta), and chondroitin sulphate (human aorta) were run alongside urine concentrates. Glycosaminoglycan fractions were located by staining with alcian blue, and quantitated by reflectance densitometry using the Joyce Chromoscan. The method was described in detail by Manley and Williams (1969).

TESTICULAR HYALURONIDASE DIGESTION
Urine concentrate (10 μl) and testicular hyaluronidase solution (10 μl, containing ovine testicular hyaluronidase (British Drug Houses Limited) 10 mg in 0.9% w/v NaCl) were mixed and incubated at 37°C for four hours. Control 'digests' of urine concentrate (10 μl) and NaCl solution (0.9% w/v, 10 μl) were treated in the same way. Digests and controls (10 μl) were examined side-by-side by electrophoresis on cellulose acetate membrane, as described above.

STREPTOMYCES HYALURONIDASE DIGESTION
Urine concentrate (20 μl) and streptomyces hyaluronidase solution (10 μl containing streptomyces hyaluronidase (Miles Research Products Limited) 10 TRU, in 0.9% w/v sodium chloride solution) was mixed and incubated at 37°C for 24 hours. Saline control samples (20 μl urine concentrate plus 10 μl 0.9% NaCl) were treated in the same way. Digests and controls (10 μl) were examined side-by-side by electrophoresis on cellulose acetate membrane, as described above.

Results
The major results of this study are shown in the Table. Of the 24 cases of disseminated neoplasm, 12 (50%) showed unequivocal radiological and/or clinical evidence of skeletal involvement by the neoplasm. Of these, eight (66%) showed raised serum alkaline phosphatase, five (42%) showed increased urinary excretion of hydroxyproline, and three (25%) showed increased urinary excretion of uronic acid.

If increased urinary excretion of hydroxyproline was taken as the criterion for skeletal involvement by neoplasm, the number of cases with skeletal involvement was seven (29% of the total), and, of these, four (57%) showed increased excretion of uronic acid.

Of the 12 cases with no clear radiological and/or clinical evidence of skeletal involvement by neoplasm, six (50%) showed raised alkaline phosphatase, two (17%) showed increased urinary hydroxyproline excretion, and four (33%) showed increased urinary uronic acid excretion. However, it might be misleading to place too much emphasis on these figures, since it is impossible to be certain that the skeleton was not involved by neoplasm in these cases.

The correlation between urinary hydroxyproline and uronic acid excretion was poor. Of the seven cases with increased urinary hydroxyproline excretion, three (43%) did not show increased urinary uronic acid excretion, and of the seven cases with
in disseminated neoplasm

Table Clinical and biochemical data on 24 cases of disseminated neoplasm

<table>
<thead>
<tr>
<th>Sex</th>
<th>Age</th>
<th>Diagnosis</th>
<th>Treatment*</th>
<th>Skeletal metastases</th>
<th>Serum Alk. Phos. (IU/l)</th>
<th>Urinary Hyaluronic acid</th>
<th>Urinary IgG or IgA myeloma</th>
<th>Urinary electrophoresis</th>
<th>Streptomyces hyaluronidase lability</th>
</tr>
</thead>
<tbody>
<tr>
<td>F</td>
<td>78</td>
<td>IgA myeloma</td>
<td>C, X, St</td>
<td>+</td>
<td>55 19 1:85 28:5 7:3 16:6 47:6</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F</td>
<td>61</td>
<td>Ca. ovary</td>
<td>C</td>
<td>-</td>
<td>75 12 1:09 32:6 0 23 44:4 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F</td>
<td>52</td>
<td>Ca. breast</td>
<td>C</td>
<td>+</td>
<td>230 28 1:45 9:1 4:8 20 66:1 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M</td>
<td>62</td>
<td>IgG myeloma</td>
<td>C, St</td>
<td>-</td>
<td>45 21 2:20 24:8 0 28:4 46:8 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M</td>
<td>71</td>
<td>IgG myeloma</td>
<td>0</td>
<td>-</td>
<td>50 12 1:24 34:9 0 21 44:1 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F</td>
<td>70</td>
<td>Ca. breast</td>
<td>C, Su, X</td>
<td>-</td>
<td>62 27 1:59 21:7 0 13 6:4 6 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F</td>
<td>65</td>
<td>Ca. breast</td>
<td>Su, X, C</td>
<td>+</td>
<td>100 58 1:87 30:6 3:5 14:7 51:2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M</td>
<td>48</td>
<td>IgG myeloma</td>
<td>C</td>
<td>+</td>
<td>33 17 1:64 23:9 0 26:5 49:6 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F</td>
<td>56</td>
<td>Ca. ovary</td>
<td>C</td>
<td>-</td>
<td>125 44 6:79 13:4 0 53:1 33:5 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F</td>
<td>50</td>
<td>Ca. ovary</td>
<td>C, Su, X</td>
<td>-</td>
<td>102 21 1:96 36:2 0 19:9 44:9 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F</td>
<td>60</td>
<td>Ca. ovary</td>
<td>0</td>
<td>+</td>
<td>156 41 1:52 13:9 4:7 21:9 59:5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F</td>
<td>58</td>
<td>Ca. breast</td>
<td>Su, X, C</td>
<td>+</td>
<td>51 27 0:86 27:3 0 24:1 48:6 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F</td>
<td>60</td>
<td>Ca. breast</td>
<td>Su, X, C</td>
<td>+</td>
<td>79 13 1:63 27:9 0 17 55:1 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F</td>
<td>53</td>
<td>Ca. breast</td>
<td>Su, X, C</td>
<td>+</td>
<td>130 42 2:23 32:2 0 33:9 33:9 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F</td>
<td>59</td>
<td>Ca. breast</td>
<td>Su, X, C</td>
<td>-</td>
<td>46 10 1:50 32:9 0 20:5 46:6 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F</td>
<td>45</td>
<td>Ca. breast</td>
<td>Su, C, St</td>
<td>+</td>
<td>426 74 2:35 8:3 5:3 33:7 52:7</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M</td>
<td>34</td>
<td>Ca. caecum</td>
<td>Su, C</td>
<td>-</td>
<td>697 22 1:52 15:5 0 40 44:5 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F</td>
<td>45</td>
<td>Ca. breast</td>
<td>mono. leukaemia</td>
<td>Su, X</td>
<td>-</td>
<td>31 22 5:38 34:0 0 66 0 0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F</td>
<td>71</td>
<td>Ca. breast</td>
<td>X, C, St</td>
<td>-</td>
<td>257 31 4:21 41:0 0 14:1 44:9 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F</td>
<td>51</td>
<td>Ca. breast</td>
<td>Su, X, C</td>
<td>-</td>
<td>142 31 0:89 43:6 0 18:2 38:2 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M</td>
<td>57</td>
<td>Ca. colon</td>
<td>C, Su</td>
<td>+</td>
<td>1000 51 9:88 14:4 5:0 43:2 37:3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M</td>
<td>71</td>
<td>IgA myeloma</td>
<td>X, C, St</td>
<td>+</td>
<td>185 14 1:07 40:1 0 16:6 43:3 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M</td>
<td>59</td>
<td>IgA myeloma</td>
<td>X, C, St</td>
<td>+</td>
<td>116 28 4:3 26:8 9:8 26:2 37:2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F</td>
<td>30</td>
<td>Turner's syndrome, embryonal abdominal tumour</td>
<td>0</td>
<td>-</td>
<td>99 37 3:97 38:8 0 21:3 39:9 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C = chemotherapy; X = radiotherapy; St = steroid therapy; Su = surgery; 0 = no treatment.

* Clear radiological and/or clear clinical evidence of skeletal involvement.

† No clear evidence of skeletal involvement (not necessarily no skeletal involvement).

Conversion: SI to traditional units — Hydroxyproline/creatinine: mg/g = mmol/mol x 1.16. Uronic acid/creatinine: mg/g = mmol/mol x 1.72

Increased urinary uronic acid excretion, three (43%) did not show increased urinary hydroxyproline excretion.

The urinary hexosamine:creatinine ratio was generally slightly higher than the uronic acid:creatinine ratio. The correlation between urinary uronic acid and hexosamine excretion was good, all cases with increased uronic acid excretion showing a similar increase in hexosamine excretion (Fig. 1).

Electrophoresis of urine concentrate produced the three alcian blue-positive fractions described by Manley et al. (1968) in 23 of the 24 cases (96%), fraction E1 corresponding with chondroitin and dermatan sulphates, fraction E2 corresponding with heparan sulphates, and the complex fraction E3 corresponding with glycoproteins (Figs 2 and 3). Testicular hyaluronidase digestion destroyed approximately 80% of fraction E1, indicating the low content of dermatan sulphate. Fractions E2 and E3 were resistant to digestion by testicular hyaluronidase.

Cases of increased urinary uronic acid excretion did not show a consistent pattern on electrophoresis of urinary glycosaminoglycans. It was not possible to attribute the increased uronic acid excretion to an increase in any one alcian blue-positive electrophoretic fraction.

The most unexpected and striking finding on electrophoresis of the urinary glycosaminoglycans was the appearance of a well-defined fraction, which is not normally identifiable by these methods in adult human urine (Manley et al., 1968). This fraction (EX) occurred as a sharply defined alcian blue-positive band in seven of the 24 urine samples (29%). The electrophoretic mobility of this fraction was identical with that of the hyaluronic acid identified in neonatal urine (Manley et al., 1968), hyaluronic acid from human umbilical cord (Manley et al., 1968).
and hyaluronic acid from human aorta (Manley, 1965). It was destroyed by digestion with testicular hyaluronidase and streptomycin hyaluronidase (Table). Fraction EX was not identified in the 12 cases with no clear evidence of skeletal involvement but occurred in seven (58%) of the 12 cases showing clear evidence of neoplastic involvement of bone.

Within the group showing clear evidence of skeletal secondaries, the ‘hyaluronic acid excretors’ differed from the ‘non-excretors’ in showing a more consistent elevation of serum alkaline phosphatase (86% of hyaluronic acid excretors compared with 40% of non-excretors), urinary hydroxyproline (57% compared with 20%), and urinary uronic acid (43% of excretors compared with 0% non-excretors).

No clear correlation was found between the biochemical parameters included in this study and the treatment the patients were undergoing (Table).

**Discussion**

The primary premise of this study—that neoplastic invasion of bone might result in an increase in urinary glycosaminoglycan excretion as well as urinary hydroxyproline excretion—has been partially confirmed, but it is clear that not all cases showing increased hydroxyproline excretion also show an increased glycosaminoglycan excretion. If urinary hydroxyproline excretion is accepted as an index of bone resorption in metastatic neoplasm (Bonadonna et al., 1966), it appears that urinary uronic acid is a less sensitive index, since only 57% of cases with an increased hydroxyproline excretion showed an increased uronic acid excretion. On the basis of this study, urinary uronic acid excretion cannot be recommended as an alternative to urinary hydroxyproline excretion for the assessment of bone resorption in metastatic neoplasm.

One case in this study (case 18) showed an increase in urinary uronic acid excretion without any evidence of bone resorption as judged by clinical evidence, X-ray studies, serum alkaline phosphatase, and urinary hydroxyproline excretion. However, bone was involved in the neoplastic process, as shown by sternal marrow biopsy, which revealed sheets of leukaemic cells. The urinary glycosaminoglycan excretion in this case was most atypical, there being a large fraction corresponding with heparan sulphates (E2) and no detectable fraction corresponding with chondroitin sulphates (E1). Glycosaminoglycans have been isolated from blood leucocytes (Fedorko and Morse, 1965), and it is possible that excess glycosaminoglycans may be produced by leukaemic cells. It is also possible that the absence of chondroitin sulphates could be due to the liberation of degradative lysosomal enzymes from leukaemic cells. The subject of urinary glycosaminoglycan excretion in leukaemia may well repay further study.

The molar ratio of hexosamine to uronic acid in the glycosaminoglycans precipitated from urine by CPC was slightly in excess of unity. This was probably due to the presence of traces of keratan sulphate, which contains hexosamine but no uronic acid.

It is interesting to note that, of the four cases of myeloma with clear radiological evidence of bone resorption, only two showed even a slight increase in serum alkaline phosphatase, only one showed an increase in urinary uronic acid excretion and none showed an increase in urinary hydroxyproline excretion. Possibly the mechanism of bone resorption in myeloma differs from that of other neoplasms.

The most interesting and remarkable outcome of this study was the discovery of a fraction indistinguishable from hyaluronic acid in urine from seven of the 12 cases with neoplastic involvement of bone. Although the presence of hyaluronic acid is a feature of neonatal urine (Manley et al., 1968), and is present in high concentration in fetal connective tissues, its concentration in most connective tissues (such as vascular tissue, Manley, 1965) declines throughout adult life and is not normally identifiable as a separate fraction in adult human urine by
Urinary excretion of glycosaminoglycans in disseminated neoplasm

Fig. 2  Alcian blue-stained electrophoretic strip showing (a) streptomyces hyaluronidase digest of urine concentrate and (b) saline-treated control. Note the destruction of fraction EX by streptomyces hyaluronidase. Technical details given in text. Case 16.

Fig. 3  Chromoscan traces of alcian blue-positive fractions (E1, E2, EX, and E3) on cellulose acetate electrophoresis of urine concentrate: (a) saline-treated control; (b) testicular hyaluronidase digest; (c) saline-treated control; (d) streptomyces hyaluronidase digest. Electrophoretic migration from left to right. The vertical arrow above the trace, and the spot beneath it, mark the position of a marker sample of hyaluronic acid from human umbilical cord. Technical details are given in the text. Case 1.

the techniques used in this study (Manley et al., 1968). Excretion of significant amounts of hyaluronic acid in adult human urine has been reported in the rare Werner's syndrome (Tokunaga et al., 1975) which, paradoxically, is associated with premature ageing.

Although fraction EX was not recovered in sufficient quantity to allow definitive analysis, its identical electrophoretic mobility with hyaluronic acid from human umbilical cord, neonatal urine, and aorta, its staining reaction with alcian blue, and its lability to both testicular and streptomyces hyalur-
Hyaluronic acid has been reported to be present in low concentrations in bone (approximately 3% of the total glycosaminoglycans (Hjertquist and Vejlens, 1966), and 'possibly minor traces' (Engfeldt and Hjerpe, 1976)), and it is possible that the hyaluronic acid appearing in the urine in the seven cases of neoplasm reported here was derived from bone. The hyaluronic acid of synovial fluid (Preston et al., 1965) and hyaline cartilage (Woodhead-Galloway and Hukins, 1976) is of high molecular weight, probably in excess of $10^6$ Daltons, and if bone hyaluronic acid is of similar dimensions it could appear in the urine only if the chains were degraded to a molecular weight of below $7 \times 10^4$ Daltons. Such degradation may well occur during osteolysis, but it is difficult to explain how such significant amounts of hyaluronic acid appear in the urine when the reported concentration of hyaluronic acid in bone is so low.

An alternative explanation is that hyaluronic acid may be produced by neoplastic cells. Hyaluronic acid has been identified in mesothelioma tissue (Preston et al., 1965; Motomiya et al., 1975) and in breast tumours (Takeuchi et al., 1976). Further studies are required to determine whether the urinary hyaluronic acid identified in cases of disseminated neoplasm is of skeletal or tumour origin.

Hyaluronic acid may be regarded as a characteristically 'fetal' glycosaminoglycan, and the reversion of a neoplastic cell to a 'fetal' type of glycosaminoglycan synthesis would be a most interesting phenomenon in the context of cancer biology. Several protein-based molecular species which are normally present in the fetus but disappear in the adult (for example, carcinoembryonic antigen, alphafetoprotein) may reappear as a result of synthesis by neoplastic cells. It is possible that the appearance of hyaluronic acid in the urine of some adults with disseminated neoplasm is an analogous phenomenon. If this proves to be the case, it would be another example of the reversion of a neoplastic cell to a more primitive (less differentiated) state, but would be of additional interest to the appearance of oncofetal antigens, because glycosaminoglycans are not thought to be coded directly by the nuclear DNA.

We thank Dr I. G. McGill, consultant physician, Torbay Hospital, for his helpful co-operation in this study.

References


Reports and Bulletins prepared by the Association of Clinical Biochemists

The following reports and bulletins are published by the Association of Clinical Biochemists. They may be obtained from The Publishing Department, British Medical Journal (ACB Technical Bulletins), B.M.A. House, Tavistock Square, London WC1H 9JR. Overseas readers should remit by British Postal or Money Order.

SCIENTIFIC REVIEWS (price £1.00/$2.00 each)

1 The assessment of thyroid function March 1971 F. V. Flynn and J. R. Hobbs
3 Biochemical tests for the assessment of fetoplacental function May 1975 C. E. Wilde and R. E. Oakley
4 Test of exocrine pancreatic function March 1977 A. H. Gownenlock

TECHNICAL BULLETINS (price £1.00/$2.00 each)

22 Bilirubin standards and the determination of bilirubin by manual and technicon AutoAnalyzer methods January 1971 Barbara Billing, Ruth Haslam, and N. Wald
23 Interchangeable cells for spectrophotometers and fluorimeters September 1971 S. S. Brown and A. H. Gownenlock
24 Simple tests to detect poisons March 1972 B. W. Meade et al.
25 Blood analysers May 1972 K. Dixon
26 Kits for enzyme activity determination September 1972 S. B. Rosalki and D. Tarlow
27 Assessment of pumps suitable for incorporation into existing continuous flow analytical systems November 1972 A. Fleck et al.